Development	development	O	O	O	O
of	of	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
after	after	O	O	O	O
switch	switch	O	O	O	O
to	to	O	O	O	O
sirolimus-based	sirolimus-based	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
in	in	O	O	O	O
long-term	long-term	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Calcineurin-inhibitor	calcineurin-inhibitor	O	O	O	O
therapy	therapy	O	O	O	O
can	can	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
in	in	O	O	O	O
heart	heart	O	O	O	O
transplantation	transplantation	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
novel	novel	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
(	(	O	O	O	O
IS	is	O	O	O	O
)	)	O	O	O	O
drug	drug	O	O	O	O
sirolmus	sirolmus	O	O	OTHERS	I
(	(	O	O	O	O
Srl	srl	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
lacks	lacks	O	O	O	O
nephrotoxic	nephrotoxic	O	DISEASE	OTHERS	I
effects	effects	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
Srl	srl	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
following	following	O	O	O	O
renal	renal	O	O	O	O
transplantation	transplantation	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
cardiac	cardiac	O	O	O	O
transplantation	transplantation	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
Srl	srl	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
unknown	unknown	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
long-term	long-term	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
switched	switched	O	O	O	O
from	from	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
Srl-based	srl-based	O	O	O	O
IS	is	O	O	O	O
.	.	O	O	O	O

Concomitant	concomitant	O	O	O	O
IS	is	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
mycophenolate	mycophenolate	O	O	OTHERS	I
mofetil	mofetil	O	O	OTHERS	I
+	+	O	O	O	O
/-	/-	O	O	O	O
steroids	steroids	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Proteinuria	proteinuria	O	DISEASE	OTHERS	I
increased	increased	O	O	O	O
significantly	significantly	O	O	O	O
from	from	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
of	of	O	O	O	O
0.13	0.13	O	O	O	O
g/day	g/day	O	O	O	O
(	(	O	O	O	O
range	range	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
5.7	5.7	O	O	O	O
)	)	O	O	O	O
preswitch	preswitch	O	O	O	O
to	to	O	O	O	O
0.23	0.23	O	O	O	O
g/day	g/day	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
9.88	9.88	O	O	O	O
)	)	O	O	O	O
at	at	O	O	O	O
24	24	O	O	O	O
months	months	O	O	O	O
postswitch	postswitch	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0024	0.0024	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Before	before	O	O	O	O
the	the	O	O	O	O
switch	switch	O	O	O	O
,	,	O	O	O	O
11.5	11.5	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
high-grade	high-grade	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
(	(	O	O	O	O
>	>	O	O	O	O
1.0	1.0	O	O	O	O
g/day	g/day	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
this	this	O	O	O	O
increased	increased	O	O	O	O
to	to	O	O	O	O
22.9	22.9	O	O	O	O
%	%	O	O	O	O
postswitch	postswitch	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.006	0.006	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

ACE	ace	CHEMICALS	O	OTHERS	I
inhibitor	inhibitor	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
angiotensin-releasing	angiotensin-releasing	O	O	O	O
blocker	blocker	O	O	O	O
(	(	O	O	O	O
ARB	arb	O	O	OTHERS	I
)	)	O	O	O	O
therapy	therapy	O	O	O	O
reduced	reduced	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
development	development	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
without	without	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
had	had	O	O	O	O
increased	increased	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
42.5	42.5	O	O	O	O
vs.	vs.	O	O	O	O
64.1	64.1	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.25	0.25	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
high-grade	high-grade	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
showed	showed	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
at	at	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
follow-up	follow-up	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
39.6	39.6	O	O	O	O
vs.	vs.	O	O	O	O
29.2	29.2	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.125	0.125	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
may	may	O	O	O	O
develop	develop	O	O	O	O
in	in	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
patients	patients	O	O	O	O
after	after	O	O	O	O
switch	switch	O	O	O	O
to	to	O	O	O	O
Srl	srl	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
an	an	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Srl	srl	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
used	used	O	O	O	O
with	with	O	O	O	O
ACEi/ARB	acei/arb	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
patients	patients	O	O	O	O
monitored	monitored	O	O	O	O
for	for	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
and	and	O	O	O	O
increased	increased	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

